Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form DEFA14A

LA JOLLA PHARMACEUTICAL CO Form DEFA14A November 25, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant b Filed by a Party other than the Registrant o Check the appropriate box:

- o Preliminary Proxy Statement
- o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- o Definitive Proxy Statement
- b Definitive Additional Materials
- o Soliciting Material Pursuant to §240.14a-12

LA JOLLA PHARMACEUTICAL COMPANY

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- b No fee required.
- o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

Common Stock, par value \$0.01

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth

the amount on which the filing fee is calculated and state how it was determined):

- (4) Proposed maximum aggregate value of transaction:
- (5) Total fee paid:

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form DEFA14A

o	Fee paid previously with preliminary materials.
O	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid:
	(2) Form, Schedule or Registration Statement No.:
	(3) Filing Party:
	(4) Date Filed:

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form DEFA14A

On November 25, 2009, La Jolla Pharmaceutical Company issued the following press release:

FOR IMMEDIATE RELEASE

LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES THE ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS

SAN DIEGO, NOVEMBER 25, 2009 La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the *Company*) today announced that its Special Meeting of Stockholders, which was originally convened on October 30, 2009 and subsequently adjourned twice, was adjourned for a third time on November 24, 2009 and has not been scheduled to be reconvened. As described in the Proxy Statement distributed to stockholders on or about October 7, 2009, the stockholders of the Company were being asked to vote upon a proposal to approve the liquidation and dissolution of the Company pursuant to a plan of liquidation and dissolution. Approximately ninety-two percent (92%) of the Company s stockholders failed to return their proxy cards or otherwise indicate their votes with respect to this proposal prior to the start of the stockholders meeting. To pass, this proposal required the approval by holders of at least a majority of the Company s outstanding voting shares. Because the Company has not been able to obtain the requisite stockholder vote to approve the Company s dissolution, it is evaluating its options and will announce future plans when it has determined what is the best course of action to follow to obtain maximum value for its stockholders.